Muhyaldee Dia, MD
Advanced Heart Failure and Transplant Cardiology · Oak Lawn, ILNPI 1851384663
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,231 of the $124,545 with a category attached, or 78.1%. United Therapeutics Corporation accounts for 76.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $44,649 and has fallen 99.6% since, to $160 in 2025.
Across 172 payments — averaging $724.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$95K
- Bayer$27K
- AstraZeneca$2K
- Johnson & Johnson$282
- Actelion Pharmaceuticals US, Inc.$243
- Novartis$196
- plus $320 from 9 others
Across 49 payments — averaging $2781.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$45K
- Actelion Pharmaceuticals, Ltd$37K
- United Therapeutics Corporation$32K
- Bayer$22K
What the payments were for
- Consulting fees$13,79011%
- Speaking & faculty fees$97,23178%
- Travel & lodging$7,4736%
- Food & beverage$5,9315%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 110 | $94,832 |
| Bayer | 22 | $27,173 |
| AstraZeneca | 4 | $1,500 |
| Johnson & Johnson | 7 | $282 |
| Actelion Pharmaceuticals US, Inc. | 5 | $243 |
| Novartis | 9 | $196 |
| Abbott | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Abiomed | 1 | $32 |
| Heartflow, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $28 |
| Cvrx, Inc. | 1 | $27 |
| Merck | 1 | $16 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,545 in reported general payments places this provider in the 85th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 149 | $3,679,668 |
| UptraviSelexipag | 59 | $1,363,026 |
| OpsumitMacitentan | 65 | $822,758 |
| AdempasRiociguat | 42 | $597,699 |
| WinrevairSotatercept-Csrk | 26 | $422,099 |
| RemodulinTreprostinil Sodium | 16 | $143,305 |
| LetairisAmbrisentan | 11 | $140,952 |
| EliquisApixaban | 146 | $129,292 |
| Ambrisentan | 14 | $54,771 |
| EntrestoSacubitril/Valsartan | 44 | $48,229 |
| XareltoRivaroxaban | 28 | $25,550 |
| JardianceEmpagliflozin | 27 | $23,074 |
| Bosentan | 12 | $16,802 |
| Tadalafil | 22 | $12,964 |
| FarxigaDapagliflozin Propanediol | 11 | $3,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Bosentan | $243 | $2,202,586136 claims |
| BayerAdempas | $27,173 | $597,69942 claims |
| MerckWinrevair | $16 | $422,09926 claims |
| United Therapeutics CorporationRemodulin | $94,832 | $143,30516 claims |
| NovartisEntresto | $196 | $48,22944 claims |
| Johnson & JohnsonXarelto | $282 | $25,55028 claims |
| Boehringer IngelheimJardiance | $28 | $23,07427 claims |
| AstraZenecaFarxiga | $1,500 | $3,10111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Oak Lawn
- Sunil PauwaaOak Lawn$62K
- Ambar AndradeOak Lawn$35K
- William CottsOak Lawn$8K
- Vinh ChauOak Lawn$7K
- Christopher SciamannaOak Lawn$930
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.